Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
33 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D3.48 - The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital
D3.53 - A retrospective audit of NSAID hypersensitivity in children and young people in a tertiary paediatric allergy centre
D3.55 - Synthetic folic acid allergy
D3.47 - Implementing Penicillin Delabelling in an Inpatient setting
D3.49 - Clinical significance and safety of provocation test for drug allergy diagnosis in outpatient unit: A real world observational study
D3.50 - Penicillin-allergic labelled patients with a PEN-FAST score of 0 could safely be de-labelled by non-allergists
D3.51 - Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists
D3.54 - Hypersensitivity reactions during therapy with platinum compounds and taxanes – who can benefit from consulting an allergist?
D3.56 - Relevant Aspects in the Investigation of Hypersensitivity Reactions to Non-Beta-Lactam Antibiotics
D3.57 - Isoniazid-Induced Lupus in a Filipino Female: A Case Report
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download